HCWB vs HOWL

HCW Biologics Inc. vs Werewolf Therapeutics, Inc. — Valuation Comparison 2026

HCWB

Biotechnology
HCW Biologics Inc.
Quality
3.9
out of 10
Value Trap
38
LOW
Price
$2.09
Last close
Models
6/13
Active
VS

HOWL

Biotechnology
Werewolf Therapeutics, Inc.
Quality
4.1
out of 10
Value Trap
30
LOW
Price
$0.46
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType HCWB Fair ValueHCWB Upside HOWL Fair ValueHOWL Upside
Bayesian DCF Intrinsic $0.18 -59.9%
Earnings Power Value Intrinsic $0.29 -35.1%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.08 -81.1% $0.05 -93.6%
Dynamic NAV Asset-Based $0.35 -83.3% $1.41 +208.9%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for HCWB vs HOWL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

HCWB vs HOWL — Which Stock Is More Undervalued?

HOWL scores higher with a 4.1/10 quality rating vs HCWB's 3.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing HCW Biologics Inc. (HCWB) and Werewolf Therapeutics, Inc. (HOWL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

HCWB currently trades at $2.09 with a QOC of 3.9/10, while HOWL trades at $0.46 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).